MedTrace Logo

Nitric Oxide in Myocardial Infarction Size

NCT00568061 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful percutaneous coronary intervention.

Conditions

  • Acute Myocardial Infarction
  • ST Elevation MI
  • STEMI

Interventions

DRUG

Nitric Oxide

Nitric oxide for inhalation

DRUG

Placebo

Nitrogen gas (placebo) for inhalation

Sponsors & Collaborators

  • Mallinckrodt

    lead INDUSTRY

Principal Investigators

  • James Baldassarre, MD · Mallinckrodt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Belgium
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568061 on ClinicalTrials.gov